Idiosyncratic Toxicity: A Convergence of Risk Factors
- 1 February 2007
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 58 (1) , 17-34
- https://doi.org/10.1146/annurev.med.58.072905.160823
Abstract
The therapeutic margin for any drug is based on both toxicity and efficacy. Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target. However, idiosyncratic toxicities are usually not observed until a drug has been on the market and has gained broad exposure. Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors. Drug-related risk factors include metabolism, bioactivation and covalent binding, and the inhibition of key cell functions. Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, physical activity, and genetic predispositions. Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.Keywords
This publication has 90 references indexed in Scilit:
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- Aerobic exercise and muscle metabolism in patients with mitochondrial myopathyMuscle & Nerve, 2005
- Herb-Drug InteractionsDrugs, 2005
- Adverse hepatic drug reactions: inflammatory episodes as consequence and contributorChemico-Biological Interactions, 2004
- Drug Treatment of Epilepsy in Elderly PeopleDrugs & Aging, 2003
- Reported Adverse Drug Events in Infants and Children Under 2 Years of AgePublished by American Academy of Pediatrics (AAP) ,2002
- Is Gender a Risk Factor for Adverse Drug Reactions?Drug Safety, 2001
- Reye's Syndrome in the United States from 1981 through 1997New England Journal of Medicine, 1999
- Mitochondrial Injury Lessons from the Fialuridine TrialDrug Safety, 1997
- Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicityPediatric Neurology, 1997